Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies

NCT02569476 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT02569476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02569476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
January 13, 2016
Completion date
September 2, 2020
Enrollment
119 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoid malignancies